pegylated liposomes | peg liposomes | liposomes research report

RITMIR028: Liposomes – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 1
LIPOSOMES MARKET SIZE
Scope of the Study
This market insight report on Liposomes gives an insight into global Liposomes market. The report provides
market analytics by application, and by therapeutic area. The market is divided by Application into
Therapeutic, Cosmetic and Other; and by Therapeutics into Antifungal, Anticancer, Ophthalmic and Other.
The study also provides information regarding products and technologies in the field of Liposomes.
Business profiles of 46 major companies are discussed in the report. The report covers more than 330
companies that are engaged in Liposomes research and supply of products and/or services. Compilation of
Worldwide Patents and Research related to Liposomes is also provided. Projections and estimates are also
illustrated by geographic regions encompassing North America, Europe, Asia-Pacific, and Rest of World with
97 exclusive graphically represented exhibits. Information related to recent product releases, product
developments, partnerships, collaborations, mergers and acquisitions, and other areas of concern is also
covered in the report.
Liposomes’ report is an ideal research tool providing strategic business intelligence to the corporate sector.
This report may help strategists, investors, laboratories, pharmaceutical companies, contract research
organizations, biotechnology companies and drug approval authorities in--
 Gauging Competitive Intelligence
 Identifying Key Growth Areas and Opportunities
 Understanding Geographic Relevance to Product
 Knowing Regional Market Sizes and Growth Opportunities and Restraints
 Keeping Tab on Emerging Technologies
 Equity Analysis
 Tapping New Markets
Analytics and data presented in this report pertain to several parameters such as –
 Global and Regional Market Sizes, Market Shares, Market Trends
 Product (Global and Regional) Market Sizes, Market Shares, Market Trends
 Technology Trends
 Corporate Intelligence
 Key Companies by Sales, Brands, Products
 Consumer Behavioral Patterns

 Other Strategic Business Affecting Data
Research Methodology
RI Technologies publishes business intelligence reports by going through a cycle of diligent research and
analysis activity. Research is done using both online and offline resources. The study outline of this report is
sketched on the following lines – global market analysis, regional market analysis, product segmentation,
global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape,
technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is
also helpful for doing market evaluations, and estimating the market size for the future.
This report is uniquely researched and the methodology includes:
 Need and Scope of Study
 Product Definitions
 Segmental Analysis
 Regional Analysis
 Exclusive Data Analytics
 Corporate Intelligence
 Feedback
Right from concept to final compilation of this report, both primary and secondary research methods are
applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the
information for authentication of our own findings. Secondary research includes government publications,
investment research reports, web based surveys, website information of both companies and markets, and
other offline resources such as print publications and CDs.
Our compilation of easy to navigate PDF reports are essential value addition resources for leading and
growing companies.

II - REPORT SYNOPSIS
Liposomes are nano sized artificial vesicles of spherical shape composed of a bilayer membrane that can be
produced from natural phospholipids and cholesterol. Liposomes are composed of naturally-derived
phospholipids which when combined with water immediately forms a bi-layered sphere. Liposomes contain
a core of aqueous material; lipid spheres that contain no aqueous material are called micelles,
The size of these spheres is very small, in the order of a nanometer. Because of the small size of the
phospholipid molecule and microspheres, they can pass through the epidermis and act as a carrier for the
enclosed substances.
Liposomes also comprise small deposits that may contain an antibiotic, antigen, allergen, drug substance or
even a gene. Liposomes are capable of entering the body without causing an immune rejection or
hypersensitivity reaction.
Segmentation of Liposomes Market
Exhibit 1. Segmentation of Global Liposomes Market by Application
Application
Therapeutic
Cosmetic
Other*
© RIT, 2013
* Includes Agro-Food, Paints (Water Based, Resins, Self Healing Paints),
Neutraceuticals, and Diagnostics
Liposomal Formulations Used in Medical Practice
Liposomes belong to the class of nanosized unilamellar phospholipid bilayer vesicles. These are considered
as the most promising and comprehensively studied drug delivery vehicles. The applications of the
Liposome-formulated drugs have enhanced over the years and they are now part of the cancer treatment
and systemic or local fungal infections. The unique feature of the Liposome-formulated drugs to remain
biologically inert, biocompatible and restricting the cause of unwanted toxic or antigenic reactions have
helped it maintain a high level of popularity in the field of drug research. The horizon and application of
Liposomes have enormously undergone transformations owing to its use in the treatment of solid tumors.
The tumors are targetted with Liposomes containing bisphosphonate which reduces the tumor associated
macrophages. The Other important developments like use of genetic components as therapeutic molecules
are the advancements in the field of delivery systems have further enhanced the scope of Liposomes based
therapy. The components of Liposomes present in the lipid-DNA complexes commonly called lipoplexes,
combat with the viral gene transfection systems. The excellent flexibility, applicability and the enormous
properties of Liposomal formulations are expected to remain as the emerging drug delivery resources.

Segmentation of Liposomes Market by Therapeutic Application
Global Liposomal Therapeutic market is segmented by therapeutic area into Antifungal, Anticancer,
Ophthalmic and Other.
Exhibit 2. Segmentation by Therapeutic Application
Therapeutic
Antifungal
Anticancer
Ophthalmic
Other*
© RIT, 2013
*Includes vaccines (Influenza, Hepatitis), Prostaglandins, Antimalarials,
Cardiovascular Diseases, Dermatology, Analgesics

Global Market Analysis
Exhibit 3. Liposomes– Global Market Estimations and Predictions (2005 – 2020) in US$ Billion
Year Value
2005 XX.XX
2006 XX.XX
2007 XX.XX
2008 XX.XX
2009 XX.XX
2010 XX.XX
2011 XX.XX
2012 XX.XX
2013 XX.XX
2014 XX.XX
2015 XX.XX
2016 XX.XX
2017 XX.XX
2018 XX.XX
2019 XX.XX
2020 XX.XX
CAGR % XX.XX
© RIT Figures, 2013
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Billion

III. MARKET DYNAMICS
Liposomes and Pharmaceuticals
Cosmeceutical and pharmaceutical markets today boast a wide range of topical products that have many
active ingredients. A common ingredient in many topical application creams and lotions are liposomes that
act as a protective mechanism while also moisturizing the skin. These liposomes are nothing but spherical
vesicles that comprise phospholipids having an aqueous core and contain lipophilic or hydrophilic active
ingredients. Depending on their properties, these dermal applications can penetrate into the skin to carry
these actives to the target site where the molecules get released. Liposomes have improved the efficiency
of many such dermal applications by improving their level of penetration into the skin. They were first used
by cosmetic giant Christian Dior in 1986 in a product named Capture. However, today the use of
nanotechnology in cosmetics is under consideration and therefore it is important to understand the
strength of this new delivery technology.
The use of liposomes in pharmaceutical products is largely for Parenteral and therefore systemic
applications. Typical examples of liposomes in pharmaceutical products are Lipofundin™ developed by
Braun Melsungen, Intralipid™ by Kabi Pharmacia and Arikace™ a liposomally encapsulated Amikacin
prescribed for lung disease. The lipid that is generally used to make these liposomes is phsophatidylcholine
that forms a part of the cell membrane and is therefore not hazardous. Liposomal cosmetics that contain
phospholipids with a flexible membrane are made of biodegradable material, for example ROVISOME®.
Liposomes and Nanotechnology
ROVISOME® is a flexible liposome that has unilamellar vesicles of very small size (approximately 50-400 nm)
and comprises more than 80% of soybean phosphatidylcholine and a large amount of linoleic acid as well.
This type of liposomes provides the skin with essential polyunsaturated fatty acids or vitamin F that
facilitate ceramide 1 formation and with choline that forms a component of NMF or natural moisturizing
factor. In an experimental study that was carried out, liposomes also exhibited other properties such as
reduction in wrinkles and also improving the smoothness of the skin. They also exhibited pharmaceutical
properties such as reducing efflorescences in the treatment of acne. In-vivo and ex-vivo studies have also
shown liposomes to have the ability to penetrate the skin. In addition the encapsulation and delivery of
hydrophilic and lipophilic actives of differing molecular sizes increases the bioavailability thereby improving
the effectiveness of the final product that is also inexpensive.

Analysis by Application
Exhibit 4. Liposomal Applications– Global Market Estimations and Predictions (2005 – 2020) for
Therapeutic, Cosmetic and Other in US$ Billion
Year/Application Liposomal Therapeutics Cosmetics Others Total
2005 XX.XX XX.XX XX.XX XX.XX
CAGR % XX.XX XX.XX XX.XX XX.XX
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Billion
LiposomalTherapeutics Cosmetics Others

Analysis by Liposomal Therapeutic Applications
Exhibit 5. Liposomal Ophthalmic Therapeutics – Global Market Estimations and Predictions (2005 – 2020)
by Geographic Region for North America, Europe, Asia-Pacific, and Rest of World in US$ Million
Year/Region North America Europe Asia-Pacific Rest of World Total
2005 XX.XX XX.XX XX.XX XX.XX XX.XX
CAGR % XX.XX XX.XX XX.XX XX.XX XX.XX
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Million
North America Europe Asia-Pacific Rest of World

Pharmaceutical Market Armed with Liposomes to Combat Fungal Infections
Globally , the instances of fungal infections are on the rise , especially in cases of people who are
immunocompromised. Immunocompromised people are incapable of developing a normal immune
response, usually as a result of disease, malnutrition, or immunosuppressive therapy. Also, there is no
decline in the count of AIDS and cancer patients. So the experts in this field are perturbed.
The therapy and diagnosis of fungal infections are implicitly arduous and demanding, especially to those
more liable to opportunistic infections. Opportunistic infection is an infection by a microorganism that
normally does not cause disease but becomes pathogenic when the body's immune system is impaired and
unable to fight off infection.
Till today the sales output of Amphocil is at a slow pace, but Abelcet is the foremost to get certified in the
United States. In November 1995, the FDA certified the drug to be harmless and is capable of causing the
intended effect in curing aspergillosis in patients who cannot withstand or are refractory to amphotericin B.
The initial sale output of company was declared to be $6 million. Market experts were expecting
certifications from FDA for by year 1996 ending for Amphotec and by year 1997 for AmBisome. All the
three drugs are expected to have the same effect as expressed by some experts like Walsh and Edward
Hurwitz, an analyst with Robertson, Stephens & Co., Only the marketing strategy and price elements will be
the determining elements.
Exhibit 6. List of Liposomal Therapeutics
S. No. Product Developer
Clearance Details
Country Year Approval Reason
1 AmBisome (liposomal
amphotericin B)
NexStar
Pharmaceuticals, Inc
Ireland 1989 Treatment of refractory
fungal infections
2 Amphocil (amphotericin
B colloidal dispersion)
Sequus
Pharmaceuticals, Inc.,
United
Kingdom
1994 Same indication as first
3 Abelcet (amphotericin B
lipid complex)
The Liposome
Company's
UK 1995 first-line therapy in the
treatment of AIDS-related
cryptoccocal meningitis and
systemic cryptococcosis
More…..
© RIT, 2013
Exhibit 7. List of Global Major Companies
S. No Company Region Website
1 Advanced Biomedical Ltd. UK www.advanced-biomedical.co.uk
2 Arboretum Skincare USA www.arboretum-skincare.com
3 Avanti Polar Lipids, Inc. USA www.avantilipids.com
4 Azaya Therapeutics, Inc. USA www.azayatherapeutics.com
5 BioZone Laboratories, Inc. USA www.biozonelabs.com
6 Luye Pharma Group Ltd. China www.luye.cn
7 SurModics Pharmaceuticals USA www.surmodicspharma.com
More…
© RIT, 2013

LIPOSOMES – THE OUTLOOK
The market for liposomes presents attractive growth opportunities, driven by growing demand for
increasingly effective drugs in the field of pharmaceuticals, and niche applications in other emerging areas.
Liposome drug delivery systems have been instrumental in the formulation of potent drugs to enhance
therapeutics. A majority of liposome formulations are designed to bring down toxicity. It is also in a limited
way formulated enhance accumulation at the target site and rendered useful in several clinical applications.
Presently pharmaceutical products of liposome-based therapeutics arise from a better understanding of
lipid-drug interactions as well as liposome disposition mechanisms. Among these mechanisms are included
the impeding of the fast clearance of liposomes. This is achieved by exercising control over surface
hydration, charge and size. Liposomes are actually lipid vesicles that are derived from self-forming enclosed
lipid bi-layers upon hydration.
Increased protection and elevated efficaciousness are being accomplished for an extensive range of drug
classes. These encompass gene therapeutics, vaccines, antimicrobials, antifungal, antiviral and anti-tumor
agents. The comprehension that is acquired from clinical use of liposome drug delivery systems can
presently be amalgamated for the design of liposomes that are targeted to tissues and cells. This could be
with or without expression of target recognition molecules on liposome membranes.
Continued improvements of bio-membrane sensors and liposome delivery systems that are competent in
the association of other membrane-bound proteins in vivo could allow selective delivery of therapeutic
compounds to chosen intracellular target areas.
As large quantities of stable and cost-effective liposomes are manufactured, many new applications will
surface. The novel applications could be self-healing paints, single tube two-component resins or glues and
water-based paints…..

IV. PRODUCT/TECHNOLOGY RESEARCH
Liposomes are nano size artificial vesicles of spherical shape composed of a bilayer membrane that can be
produced from natural phospholipids and cholesterol. Liposomes are composed of naturally-derived
phospholipids which when combined with water immediately forms a bi-layered sphere. Liposomes contain
a core of aqueous material; lipid spheres that contain no aqueous material are called micelles,
In 1961, Dr Alec D. Bangham produced the first liposomes. He was studying the relationship between blood
clotting and phospholipids. He observed that as soon as phospholipids came into contact with water, they
assumed a spherical structure. Dr. Bangham also deciphered the cause for this transformation. He noticed
that one end of the phospholipid molecule was water soluble, while the other end was not. Therefore,
when water-soluble drugs were added to water, they were enclosed or trapped within the hydrophobic
ends. The reverse was the case when fat-soluble medicaments were brought near phospholipids. Such
drugs were trapped within the phospholipid layers.
Liposomes are artificial vesicles that are made up of concentric bilayers of lipid that are separated by
compartments of water. The bilayer forming lipids are amphiphilic in nature meaning they have a polar
head group that is attached to one or maybe even two hydrophobic hydrocarbon tails. On exposure to an
aqueous medium the hydrophilic heads interact with each other and Vender Waal’s interactions are also
seen between the hydrocarbon chains. They also interact with water called hydrophilic interactions with a
hydrophobic effect that then result in a spontaneous formation of bilayers that are closed.
The size of these spheres is very small, in the order of a nanometer. Liposomes are of various sizes ranging
from those having a diameter of 20nm to others that are visible under a light microscope with a diameter
of 1 µm or bigger and similar in size to living cells. Because of the small size of the phospholipid molecule
and microspheres, they can pass through the epidermis and act as a carrier for the enclosed substances.
Liposomes are also different with respect to their lipid composition and structural organization based upon
which they can be classified into unilamellar, multilamellar and oligolamellar vesicles. Liposomes have been
made so that the solute can be surrounded by the aqueous compartment called polar solute or
alternatively be embedded in the lipid bilayers known as lipophilic or amphiphilic solutes.
Liposomes also comprise small deposits that may contain an antibiotic, antigen, allergen, drug substance or
even a gene. Liposomes are capable of entering the body without causing an immune rejection or
hypersensitivity reaction.
Phospholipids arrange themselves so as to form a membrane having a wall of hydrophilic heads that would
prevent permeation of oil droplets through it. It is also not possible for water to pass through the
membrane due to the presence of lipophilic tails of the liposomes that do not allow passage of water. The
only part of the membrane that allows passage of only certain chemicals into and out of the cell is special
protein molecules that are programmed for the purpose.
The use of liposomes in biological and biochemical research are five-fold. They include:
 Lipid-Protein interactions
 Membrane dynamics

 Delivery systems for biomolecules and small molecules into cells
 Membrane related proteins
 Regulation of protein function by lipids
Forms of Liposomes
1. Conventional forms of liposomes include
 Stabilized natural lecithin (PC) mixtures
 Synthetic identical-chain phospholipids
 Glycolipid containing liposomes
2. Special forms of liposomes are
 Bipolar fatty acid liposomes
 Antibody directed liposomes
 Methyl/ Methyane liposomes
3. x-linked liposomes
 Lipoprotein coated liposomes
 Carbohydrate wated liposomes
 Multiple encapsulated liposomes
 Emulsion compatible liposomes
Conventional liposomes are man-made liposomes that can carry and deliver drugs that can also delay their
elimination by the system. This in turn permits the drugs to stay in the bloodstream for prolonged period of
time. These liposomes when heated to a specific temperature (40ºC to 42ºC), there occurs an opening in
the liposomes thereby permitting its drug to released rapidly in the targeted area.
Exhibit 8. List of Liposome based Drugs in Clinical Trials
Trade Name Indication Company Status
Liposomal alpha-TEA (α-TEA) (cyclosporine) Rejection post lung transplantation, asthma & cancer Alulim Pharma, Inc. Preclinical
Liposomal Cyclosporine A (cyclosporine) Rejection post lung transplantation, asthma & cancer Alulim Pharma, Inc. Preclinical
ATI-0918 (Liposomal encapsulation of
doxorubicin)
Cancer Azaya Therapeutics, Inc. Preclinical
ATI-1123 (Liposomal formulation of
docetaxel)
NSCLC, gastric cancer, pancreatic cancer, and soft-
tissue sarcoma
Azaya Therapeutics, Inc. Phase II
Thermodox (Doxorubicin) Recurrent chest wall breast cancer Celsion Corporation Phase I/II
More…
About RI Technologies
RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We
emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly

monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry
based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging
technologies in areas of discovery, design and development.
Research – As Good as the Methodology is!
 Gauging Competitive Intelligence
 Identifying Key Growth Areas and Opportunities
 Understanding Geographic Relevance to Product
 Knowing Regional Market Sizes and Growth Opportunities and Restraints
 Keeping Tab on Emerging Technologies
 Equity Analysis
 Tapping New Markets
© COPYRIGHT
The copyright and publication rights to all RI Technologies' reports and other products are the property of
the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of
the material without express permission is not allowed. The buyer, under no circumstances, shall license,
resell or repackage, or sell data without prior permission of the company.
DISCLAIMER
RI Technologies sells content in good faith. The company is not liable to the buyer for any implications
arising out of the usage of data for any particular purpose. The company makes no representations or
warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for
data compilation and presentation, the company does not accept any responsibility for findings in the study
which are a cumulative effort of primary and secondary research resources. The studies do not endorse or
promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are
not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage
of the data.

pegylated liposomes | peg liposomes | liposomes research report

Recomendados

Recomendados

Más contenido relacionado

Más de Research Impact

Más de Research Impact (11)

Último

Último (20)

pegylated liposomes | peg liposomes | liposomes research report